AI Engines For more Details: Perplexity Kagi Labs You
Skin Health: Nicotinamide is commonly used topically to treat various skin conditions due to its anti-inflammatory and anti-microbial properties. It is used in the treatment of acne vulgaris, where it helps reduce inflammation and the production of sebum, leading to fewer acne lesions. Nicotinamide is also used to treat other skin conditions like rosacea, eczema, and dermatitis.
Skin Aging: Nicotinamide has been shown to improve the appearance of aging skin by reducing fine lines, wrinkles, and hyperpigmentation. It helps enhance the skin's barrier function, increases collagen production, and reduces the degradation of elastin, leading to smoother and more youthful-looking skin.
Skin Cancer Prevention: Some studies suggest that nicotinamide may help reduce the risk of certain types of skin cancer, particularly non-melanoma skin cancers like basal cell carcinoma and squamous cell carcinoma. It is believed to exert its protective effects by repairing DNA damage caused by UV radiation and enhancing the repair mechanisms within skin cells.
Hyperphosphatemia: Nicotinamide has been investigated for its potential to lower phosphate levels in individuals with chronic kidney disease (CKD) who have hyperphosphatemia. By inhibiting the absorption of phosphate in the intestines, nicotinamide may help reduce serum phosphate levels and mitigate the risk of complications associated with CKD, such as cardiovascular disease and mineral bone disorders.
Diabetes: Nicotinamide has been studied for its role in improving beta-cell function and insulin sensitivity in individuals with type 1 and type 2 diabetes. It may help preserve beta-cell mass and function, leading to better glycemic control and reduced risk of diabetic complications. However, more research is needed to establish its efficacy and safety for diabetes management.
Neurological Disorders: Nicotinamide plays a crucial role in cellular energy metabolism and has been investigated for its potential neuroprotective effects in conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis. It may help protect neurons from oxidative stress, inflammation, and mitochondrial dysfunction, although further research is needed to confirm its therapeutic benefits.
Other Conditions: Nicotinamide supplementation may also have benefits for other conditions, including pellagra (a niacin deficiency disease), osteoarthritis, inflammatory bowel disease, and prevention of migraine headaches. However, more research is needed to fully understand its effects in these areas.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.1 | 0.1 | |
| Allergic Rhinitis (Hay Fever) | 0.2 | 0.2 | |
| Allergies | 0.4 | 0.3 | 0.33 |
| Allergy to milk products | 0.5 | 0.2 | 1.5 |
| Alzheimer's disease | 0.3 | 0.1 | 2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.2 | 0.5 | -1.5 |
| Ankylosing spondylitis | 0.8 | 0.1 | 7 |
| Anorexia Nervosa | 0.1 | -0.1 | |
| Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
| Atherosclerosis | 0.1 | 0.1 | |
| Atrial fibrillation | 0.1 | 0.3 | -2 |
| Autism | 0.4 | 0.4 | 0 |
| benign prostatic hyperplasia | 0.2 | 0.2 | |
| Bipolar Disorder | 0.3 | 0.1 | 2 |
| Carcinoma | 0.3 | 0.1 | 2 |
| Celiac Disease | 0.4 | 0.1 | 3 |
| Cerebral Palsy | 0.1 | -0.1 | |
| Chronic Fatigue Syndrome | 0.2 | 0.2 | |
| Chronic Kidney Disease | 0.2 | 0.2 | |
| Chronic Urticaria (Hives) | 0.6 | 0.1 | 5 |
| Coagulation / Micro clot triggering bacteria | 0.6 | 0.1 | 5 |
| Colorectal Cancer | 0.7 | 0.7 | |
| Constipation | 0.2 | 0.2 | |
| Coronary artery disease | 0.1 | 0.1 | |
| COVID-19 | 0.7 | 0.4 | 0.75 |
| Crohn's Disease | 0.7 | 0.1 | 6 |
| cystic fibrosis | 0.6 | 0.6 | |
| deep vein thrombosis | 0.6 | 0.1 | 5 |
| Depression | 0.6 | 0.3 | 1 |
| Eczema | 0.2 | 0.2 | |
| Endometriosis | 0.6 | 0.1 | 5 |
| Epilepsy | 0.2 | 0.2 | |
| Fibromyalgia | 0.1 | -0.1 | |
| Functional constipation / chronic idiopathic constipation | 0.7 | 0.1 | 6 |
| gallstone disease (gsd) | 0.3 | 0.3 | |
| Generalized anxiety disorder | 0.6 | 0.6 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.4 | 0.4 | |
| hyperglycemia | 0.2 | 0.2 | |
| hypertension (High Blood Pressure | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.1 | -0.1 | |
| Inflammatory Bowel Disease | 0.6 | 0.4 | 0.5 |
| Intelligence | 0.1 | -0.1 | |
| Intracranial aneurysms | 0.1 | 0.1 | |
| Irritable Bowel Syndrome | 0.7 | 0.7 | |
| Liver Cirrhosis | 0.3 | 0.1 | 2 |
| Long COVID | 0.2 | 0.3 | -0.5 |
| Lung Cancer | 0.2 | 0.1 | 1 |
| ME/CFS without IBS | 0.1 | 0.1 | |
| Metabolic Syndrome | 0.7 | 0.1 | 6 |
| Mood Disorders | 0.6 | 0.3 | 1 |
| Multiple Sclerosis | 0.1 | 0.2 | -1 |
| Multiple system atrophy (MSA) | 0.1 | -0.1 | |
| Neuropathy (all types) | 0.2 | -0.2 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.3 | 0.1 | 2 |
| Obesity | 0.3 | 0.1 | 2 |
| obsessive-compulsive disorder | 0.8 | 0.1 | 7 |
| Osteoarthritis | 0.2 | 0.1 | 1 |
| Osteoporosis | 0.3 | 0.3 | |
| Parkinson's Disease | 0.4 | 0.3 | 0.33 |
| Polycystic ovary syndrome | 0.3 | 0.2 | 0.5 |
| Psoriasis | 0.5 | 0.1 | 4 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.4 | 0.4 | |
| Rosacea | 0.1 | 0.1 | |
| Schizophrenia | 0.1 | 0.1 | 0 |
| scoliosis | 0.1 | -0.1 | |
| Sjögren syndrome | 0.3 | 0.3 | |
| Sleep Apnea | 0.1 | 0.1 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | 0.4 | |
| Stress / posttraumatic stress disorder | 0.4 | 0.4 | |
| Systemic Lupus Erythematosus | 0.2 | 0.1 | 1 |
| Tic Disorder | 0.1 | 0.1 | 0 |
| Type 1 Diabetes | 0.3 | 0.3 | |
| Type 2 Diabetes | 0.7 | 0.5 | 0.4 |
| Ulcerative colitis | 0.6 | 0.1 | 5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.